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ABSTRACT
Klinefelter syndrome is the most common chromosomal aneuploidy in men (XXY karyotype, 1 in 600 live births) and results in testicular
(infertility and androgen deficiency) and nontesticular (cognitive impairment and osteoporosis) deficits. The extent to which skeletal
changes are due to testosterone deficiency or arise directly from gene overdosage cannot be determined easily in humans. To answer
this, we generated XXY mice through a four-generation breeding scheme. Eight intact XXY and 9 XY littermate controls and 8 castrated
XXY mice and 8 castrated XY littermate controls were euthanized at 1 year of age. Castration occurred 6 months prior to killing. A third
group of 9 XXY and 11 XY littermates were castrated and simultaneously implanted with a 1-cm Silastic testosterone capsule 8 weeks
prior to sacrifice. Tibias were harvested from all three groups and examined by micro–computed tomography and histomorphometry.
Blood testosterone concentration was assayed by radioimmunoassay. Compared with intact XY controls, intact androgen-deficient XXY
micehad lowerbone volume(6.8% 1.2%versus8.8% 1.7%, mean SD, p¼.01) andthinner trabeculae(50 4mmversus 57 5mm,
p¼.007). Trabecular separation (270 20mm versus 270 20mm) or osteoclast number relative to bone surface (2.4 1.0/mm
2 versus
2.7 1.5/mm
2) did not differ significantly. Testosterone-replaced XXY mice continued to show lower bone volume (5.5% 2.4% versus
8.1% 3.5%, p¼.026). They also exhibited greater trabecular separation (380 69mm versus 324 62mm, p¼.040) but equivalent
bloodtestosteroneconcentrations(6.3 1.8ng/mLversus8.2 4.2ng/mL,p¼.28)comparedwithtestosterone-replacedXYlittermates.
In contrast, castration alone drastically decreased bone volume (p<.001), trabecular thickness (p¼.05), and trabecular separation
(p<.01) to such a great extent that differences between XXY and XY mice were undetectable. In conclusion, XXY mice replicate many
featuresofhumanKlinefeltersyndromeandthereforeareausefulmodelforstudyingbone.Testosteronedeficiencydoesnotexplainthe
bone phenotype because testosterone-replaced XXY mice show reduced bone volume despite similar blood testosterone levels.  2010
American Society for Bone and Mineral Research.
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Introduction
C
hromosomal dysjunction occurs during meiosis in all
mammalianspeciesandsometimescanresultinaneuploidal
live-birth offspring. Klinefelter syndrome (KS) is the most
frequent sex chromosome aneuploidy in human males,
occurring in 1 in 500 male conceptions, of which only five-
eights to one-half progress to full term because the correspond-
ing incidence in live male births is 1 in 800 to 1000.
(1–3) The
karyotype responsible is usually XXY,
(4,5) although higher-order
aneuploidies (XXXY and higher) can occur and are associated
with more extreme phenotypes.
(6)
KS is typified in all species examined to date (including
rodents, Siberian tigers, and Australian kangaroos) by repro-
ductive dysfunction expressed as androgen deficiency, small
testicular size, and infertility. Additional nonreproductive
features such as tall stature and osteoporosis are also
characteristic in humans but occur with early onset of or
untreatedhypogonadismfromanycause.
(6–8)Ontheotherhand,
certain behavioral, neurologic, psychiatric, and cognitive deficits
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2148are specific to KS
(9–13) and provide proof of principle that some
features of KS cannot be mediated solely by androgen
deficiency.
The features and consequences of human KS now have been
identified without ascertainment bias through national popula-
tion-based studies that link cytogenetic diagnoses with mortality
registries or hospital admissions.
(10–13) These studies confirm
an increased risk of osteoporosis
(13) and death from femoral
fracture,
(11) particularly in later life.
(14) Furthermore, it has long
been assumed that osteoporosis and increased fracture risk
occur owing to coexisting androgen deficiency rather than
KS per se, and many studies have not separated KS from other
causes of hypogonadism analytically. Consistent with this
hypothesis, both higher concurrent systemic testosterone
concentrations
(15) and shorter androgen receptor polyalanine
length (which results in greater androgen receptor transactiva-
tion)
(16)areassociatedwithhigherbonemineraldensity(BMD)in
men. Testosterone therapy administered to men with primary
hypogonadism (including those with KS) also generally improves
BMD,
(17) but normalization of bone may be incomplete in
some men with KS,
(18,19) especially if therapy is suboptimal.
(20)
Furthermore, men with KS exhibit other bone and joint
abnormalities (ie, premature fusion and excessive calcification
of coronal sutures,
(21) abnormal joint development,
(22) and
osteoarthritis
(13)) that are not typically observed in other
hypogonadal men.
For these reasons, we hypothesized that the osteoporosis
exhibited by KS men may not arise exclusively from androgen
deficiency and that genes, including those located on the X
chromosome that escape X inactivation, could be partly
responsible. Establishing the existence of such genes eventually
could unveil novel pathways important for bone architecture,
volume, or turnover. However, separating hormonal from
genetic causes requires interventional studies that cannot be
undertaken systematically in humans. We therefore developed
an XXY mouse model that exhibits androgen deficiency and
impaired learning, analogous to the hormonal, testicular, and
cognitive phenotype of human KS.
(23) The purpose of this study
was to characterize bone architecture, volume, and turnover in
intact, castrated, and simultaneously castrated and testosterone-
replaced XXY mice by static and dynamic histomorphometry,
micro–computed tomography (mCT), and dual-energy X-ray
absorptiometry (DXA).
Materials and Methods
Animals
Breeding pairs of C57BL/6J XY
  male and XX female mice were
initially purchased from the Jackson Laboratory (Bar Harbor, ME,
USA). XXY mice (41,XXY) and their littermate XY mice (40,XY)
were produced in the fourth generation from our breeding
colony, as described previously.
(23) Two separate groups of intact
(XXYn¼8,XYlittermatecontrolsn¼9)andcastrated(XXYn¼8,
XY littermate controls n¼8) mice were generated and
euthanized at age 12 to 15 months. The second group was
castrated 6 months prior to killing. A third group of littermates
(XXY n¼9, XY n¼11) was simultaneously castrated and
implanted with a 1-cm Silastic capsule of testosterone 8 weeks
priortokillingatage14to34months understandardisofluorane
anesthesia, as described previously by us.
(24) A subgroup (XXY
n¼6, XY n¼7) of this third group of mice was injected with
calcein (Sigma, Castle Hill, Australia) solution (30mg/kg of body
weight) intraperitoneally 13 and 3 days prior to killing to allow
dynamic histomorphometry and also was scanned by DXA
(Hologic 4500A using the small-animal software module,
Bedford, MA, USA) at the time of killing to examine whole-
body composition and bone density.
The animal breeding colony was established and housed in a
standardanimalfacility,3to4animalspercage,undercontrolled
temperature (228C) and photoperiod (12hours light/dark)
with free access to water and mouse chow. Animal breeding,
handling, and experimentation were in accordance with the
recommendations of the American Veterinary Medical Associa-
tion and were approved by the Harbor-UCLA Biomedical
Research Institute Animal Care and Use Review Committee.
Tissue collection and specimen preparation
At euthanization, tibias were harvested for histologic and mCT
evaluation, and plasma was collected by cardiac puncture for
later testosterone measurement. Tibias were dissected and fixed
in 4% formalin, buffered with 0.1mol/L of phosphate buffer (pH
7.4) for 24hours at 48C, and then stored in 70% ethanol for mCT
evaluation. After mCT analysis, tibias were decalcified with 10%
EDTA and embedded in paraffin. Serial 5-mm sections were
stained with hematoxylin and eosin (H&E) or fast green and
safranin-O for general histologic evaluation. To identify
osteoclasts, sections were stained for tartrate resistant acid
phosphatase (TRACP) using naphthol AS–BI phosphate (Sigma)
as a substrate and fast red violet Luria-Bertani salt (Sigma) as the
detection agent.
mCT anaylsis
mCT of tibias was performed using a Skyscan 1172 scanner
(SkyScan, Kontich, Belgium). Scanning occurred at 100kV and
100mA with a 1-mm aluminium filter, and the exposure time was
set to 590ms. In total, 1800 projections were collected for each
tibia at a resolution of 6.93mm/pixel. Sections were recon-
structed using a modified Feldkamp cone-beam algorithm with
beam-hardeningcorrectionsetto50.VGStudioMAX1.2software
(Volume Graphics GmbH, Heidelberg, Germany) produced 3D
visualizations from reconstructed sections. Trabecular and
cortical morphometry of proximal tibias were quantified with
CTAnalyser software (Version 1.02, SkyScan). The volume of
interest for trabecular bone was selected within the endosteal
borders from 0.1 to 1.1mm below the distal surface of the
proximal growth plate. Trabecular morphology was described by
bonevolumefraction[BV/tissue volume(TV)], trabecular number
(Tb.N), trabecular separation (Tb.Sp), trabecular thickness (Tb.Th),
bone surface to bone volume ratio (BS/BV), and trabecular
patternfactor (Tb.Pf),whichisan indexoftrabecular connectivity
(higher values of Tb.Pf correspond with lower connectivity).
(25)
Transverse sections of tibial cortical bone were analyzed at a
level 20% by length below the proximal end of the tibia
corresponding to approximately 3mm from the growth plate.
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Histomorphometric analysis of the proximal tibial metaphysis
was conducted in all mice. Measurements were performed
on 5-mm sections stained with TRACP, H&E, or fast green and
safranin-O using the Bioquant Osteo II System (Bioquant,
Nashville, TN, USA). The region of interest was a 1 1mm area
located 0.1mm below the growth plate of the tibia. Osteoclast
number and osteoclast surface relative to bone surface were
measured with osteoclasts identified as TRACP
þ (red-stained)
multinucleated cells in direct apposition to bone surfaces.
Osteoblasts were identified by their cuboidal morphology, and
osteoblast surface was quantified.
Fibroblast culture and karyotype analysis
Standard karyotyping was performed on cultured fibroblasts
obtained from ear clips in adult mice as described previously.
(23)
Briefly, a 1- to 2-mm
2 section of tissue was dissected from an ear
clipping. The sample was minced and digested with 1.25%
trypsin (Gibco, Invitrogen Co., New York, NY, USA) for 30minutes,
followed by collagenase (Gibco Invitrogen) for an hour and
half at 378C. The dispersed cells were suspended in Amino-
Max-II medium (Gibco, Invitrogen), which supports the
growth of anchored fibroblast cells. The cells were placed
in flasks and cultured for 5 to 7 days at 378Ci naC O 2
incubator. Once appropriate colony formation was observed,
KaryoMAX Colcemid solution (Gibco, Invitrogen) was
added to stop mitotic division. The cultured fibroblasts were
harvested after a minor digestion with trypsin-EDTA solution
(Gibco, Invitrogen). The harvested cells were suspended in
0.075M potassium chloride solution (Gibco, Invitrogen) and
incubated in a water bath at 378C for 20 minutes, fixed in a
mixture of methanol and acetic acid (3:1 methanol–acetic acid),
spread on clean glass slides, and air dried for fluorescence in situ
hybridization (FISH) analysis. Images were examined with a Zeiss
fluorescence microscope (Go ¨ttingen, Lower Saxony, Germany)
using Image-Pro Plus software (Silver Spring, MD, USA).
Testosterone assays
Plasma was stored at  208C for later measurement of
testosterone concentrations by RIA using a kit from DPC
(Coat-a-Tube, Torrance, CA, USA), as reported previously.
(23)
The minimal detection limit of the assay was 0.25ng/mL, and
the intra- and interassay coefficients of variations (CV) were
approximately 10%.
Statistical analysis
Five comparisons were planned: (1) intact XY versus intact XXY,
(2) castrated XY versus castrated XXY, (3) castrated and
testosterone-implanted XY versus castrated and testosterone-
implanted XXY, (4) intact XY versus castrated XY, and (5) intact
XXY versus castrated XXY. Student’s t tests evaluated all
comparisons, except comparison 3 because age is known to
alter bone biology. For this analysis, two-way ANOVA models
with age ( 15 months and >15 months) and karyotype (XY
versus XXY), and the interactions were constructed. Where
appropriate, models without the interaction term were con-
structed to confirm full factorial findings. Means and standard
errors of the means (SEM) are shown unless otherwise stated. For
comparisons 1, 2, and 3, p<.05 was considered statistically
significant because all comparisons were independent and
performed in separate sets of mice. For comparisons 4 and 5, a
more stringent p<.025 was considered statistically significant
using Holm’s method to sequentially correct for multiple
comparisons.
(26) All statistical analyses were performed using
SASProcTtestandMixed(SASVersion9.1,SASInstitute,Cary,NC,
USA).
Results
Plasma testosterone concentrations
Plasma hormone concentrations directly confirmed equivalent
systemic testosterone exposure in XY and XY mice after
castration and then after simultaneous castration and testoster-
one replacement. We have shown previously that plasma
testosterone concentration in intact XXY mice is less than that in
XY mice (p<.05): 2.6 0.8.1ng/dL (n¼7) and 5.7 0.8.1ng/dL
(n¼7).
(23) Plasma testosterone concentrations after castration
were undetectable. Plasma testosterone concentrations after
simultaneous castration and testosterone implantation were
increased to intact adult male mice levels and equivalently:
6.3 0.7ng/dL and 8.2 1.6ng/dL in XXY (n¼6) and XY (n¼7)
mice, respectively (p¼.28).
Fig. 1. Illustrative longitudinally orientated proximal tibial sections obtained from 3D reconstructed serial mCT sections. Micrographs from intact (left),
castrated (center), and simultaneously castrated and testosterone-treated (right) XY and XXY mice are shown. Castration results in profound loss of bone
after castration in both XY and XXY mice (center).
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Longitudinally orientated micrographs of 3D reconstructed
proximal tibial images in intact, castrated, and testosterone-
replaced XXY and XY mice are shown in Fig. 1. Profound loss of
bone occurs after castration in both XXY and XY mice.
Quantitative mCT findings (Table 1 and Fig. 2) confirm qualitative
observations (Fig. 1). Intact XXY mice are osteopenic (show
reduced bone volume, BV/TV) compared with XY mice, and
they remain so even after 2 months of equivalent testosterone
therapy (Table 1 and Fig. 2). This osteopenia is associated
with reduced trabecular thickness in intact XXY mice and
reduced trabecular number in testosterone-replaced XXY mice
compared with littermate controls (Table 1). However, trabecular
connectivity (Tb.Pf) did not differ according to karyotype in
intact, castrated, or testosterone-replaced mice (Table 1).
Six months of castration results in profound loss of bone so
that architectural differences between XXY and XY mice are no
long discernible. Castration markedly disrupts all aspects of
trabecular architecture in XY and XXY mice, except trabecular
thickness, which was relatively preserved in XXY (p¼0.91) and
XY (p¼.03; considered not significant after multiple comparison
testing) mice.
Cortical bone area and thickness in the tibias were similar
between XXY and XY mice under all three experimental
conditions (Table 1).
Bone histomorphometry
No significant differences in osteoblast or osteoclast surface in
relation to bone surface were detected between XXY and XY
mice under any of the three experimental conditions (intact,
castrated, and simultaneously castrated and testosterone-
replaced; Table 2). No differences in bone apposition rates were
observed (p¼.35).
DXA scans
DXA scans (Fig. 3) show a significant (p¼.045), persistent
reduction in total bone in the entire bodies of XXY mice after
Table 1. Tibial mCT Architecture
Tibial trabecular bone Tibial cortical bone
BV/TV
(%)
Tb.N
(1/mm)
Tb.Sp
(mm)
Tb.Th
(mm)
BS/BV
(1/mm)
Tb.Pf
(1/mm)
Area
(mm
2)
Thickness
(mm)
Intact XY 8.8 (0.6) 1.56 (0.08) 272 (7) 57.0 (1.7) 67 (2.9) 22.8 (2.0) 0.86 (0.03) 127 (4.2)
XXY 6.8 (0.4) 1.36 (0.05) 270 (8) 50.1 (1.3) 76 (2.6) 27.2 (1.4) 0.81 (0.03) 128 (4.9)
Testosterone test
XY versus XXY
0.016 0.062 0.876 0.007 0.025 0.095 0.207 0.814
Castrated XY 0.9 (0.2) 0.17 (0.03) 413 (28) 46.9 (4.5) 108 (13) 59.7 (7.1) 0.69 (0.02) 121 (7.1)
XXY 1.2 (0.2) 0.25 (0.04) 399 (13) 49.7 (2.7) 103 (9.1) 53.7 (6.1) 0.74 (0.02) 129 (3.3)
Testosterone test
XY cast versus
XXY cast
0.304 0.169 0.626 0.572 0.750 0.532 0.066 0.273
Castrated and XY 8.1 (1.1) 1.30 (0.12) 324 (19) 60.4 (3.0) 66 (3.4) 23.4 (1.6) 0.72 (0.03) 96 (5.8)
testosterone XXY 5.5 (0.8) 0.95 (0.13) 380 (23) 57.8 (2.8) 70 (3.1) 26.5 (1.7) 0.71 (0.04) 91 (7.5)
implanted ANOVA XY cast
testosterone
versus XXY cast
testosterone
0.026 0.019 0.040 0.342 0.301 0.224 0.992 0.667
Testosterone test
XY versus XYcast
0.000 0.000 0.000 0.030 0.003 0.000 0.000 0.473
Testosterone test
XXY versus XXYcast
0.000 0.000 0.000 0.913 0.015 0.001 0.093 0.874
Note: Data are mean (SEM). BV/TV is bone volume/tissue volume; Tb.N, Tb.Sp, Tb.Th, and TB.Pf are trabecular number, separation, thickness, and pattern
factor, respectively; and BS/BV is bone surface/bone volume.
Fig. 2. Tibial bone volume fraction in intact (left), castrated (center), and
simultaneously castrated and testosterone-treated (right) XY and XXY
mice. XXY mice are osteopenic compared with XY mice in the intact state
(p¼.016) as well as when simultaneously castrated and testosterone-
replaced (p¼.026). Castrated XXY and XY mice are equally (p¼.30) and
profoundly (p<.001 for both) osteopenic. Data are mean SEM.
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findings shown by mCT of the tibia (Figs. 1 and 2). Total, lean, and
fat mass did not differ significantly between XXY and XY mice
(all p>.2) under testosterone-replaced conditions.
Discussion
In this study we demonstrate that mice with an XXY genotype
present with an osteopenic phenotype, a similar finding to that
observed in men with KS. The reduction in bone mass in these
XXY mice may be due in part to impaired gonadal function.
Indeed, orchidectomy of normal and XXY mice produce
profound reductions in bone mass in both genotypes, reflecting
the potency of androgens/estrogens in maintaining bone mass.
However, XXY mice orchidectomized and concurrently testos-
terone replaced with implanted pellets for 8 weeks had
persistent reduced bone mass relative to that in similarly treated
XY littermates. Although we do not know whether the duration
ofthetestosteronetreatmentwasoptimalinrodents,theselatter
results suggest a role for genotype independent of gonadal
function in determining bone mass in XXY mice.
HereweprovidepreliminaryevidencethatX-linkedgenesthat
escape inactivation may be responsible for reductions in bone
mass. Further work is needed, but a systematic approach to
identify these genes is possible because the DNA sequence of
the X chromosome is known.
(27) Genome-wide linkage studies
also have associated BMD and area bone size with Xq27,
(28,29)
and DNA expression sequence tags, including a number with
hypothetical protein products, that escape X-inactivation have
been identified.
(30) Altogether, we provide proof of principle
that studying chromosomal aneuploidies is a useful strategy to
identify novel genes, as has been postulated for understanding
the genetic basis of psychosis.
(31)
A systematic and exhaustive examination of bone architecture
inany XXYmammal hasnotbeen performed previously. Here we
showthat(intact)adultXXYmicehaveosteopeniaandthatthisis
due to trabecular, not cortical bone changes. The predominate
change is reduced trabecular thickness rather than reduced
trabecular separation or number, and this is important because
reduced trabecular number appears to reduce bone strength
more than reduced trabecular thickness.
(32) Furthermore, the
thinning rather than loss of trabeculae is suggestive but not
conclusive of decreased bone formation.
(33) Nevertheless, bone
histomorphometry did not unveil the cellular basis for the
reduction in trabecular thickness because osteoblast and
osteoclast surface areas were each comparable with those of
XY littermate controls. The lack of difference in static cell
measurements betweenXXYandXYmicemayreflect alteredcell
function (rather than cell appearance or number). Alternatively,
the cellular changes leading to bone loss may have occurred
earlier during skeletal development and may no longer be
apparent in mature mice.
(34)
Orchidectomy in XXY and XY mice resulted in marked loss of
bone and profoundly disrupted trabecular architecture to a similar
extent in both genotypes. Trabecular separation was increased,
whereas trabecular number and connectivity were decreased
(each p .001). However, trabecular thickness was not changed
(p¼.91). These results highlight the importance of androgens and
Table 2. Tibial Histomorphometry
Ob.S/BS (%) Oc.S/BS (%) N.Oc/BS (1/mm)
Intact XY 8.6 (1.6) 9.7 (1.8) 2.67 (0.61)
XXY 12.2 (3.1) 10.5 (2.0) 2.43 (0.39)
Testosterone test XY versus XXY 0.301 0.776 0.743
Castrated XY 9.5 (2.0) 16.3 (3.0) 4.79 (0.8)
XXY 14.9 (3.5) 16.5 (3.3) 3.71 (0.75)
Testosterone test XY cast versus XXYcast 0.251 0.962 0.352
Castrated and XY 4.2 (0.7) 2.8 (0.8) 1.39 (0.34)
testosterone XXY 1.7 (1.1) 1.9 (0.4) 1.58 (0.39)
implanted Testosterone test XY cast versus XXY cast 0.083 0.44 0.352
Testosterone test XY versus XY cast 0.713 0.087 0.061
Testosterone test XXY versus XXYcast 0.570 0.155 0.173
Note: Data are mean (SEM). Ob.S/BS and Oc.S/BS are obsteoblast and osteoclast surface relative to bone surface, respectively; N.Oc/BS is osteoclast
number relative to bone surface.
Fig. 3. BMD measured by DXA in castrated and simultaneously castrated
and testosterone-treated XY and XXY mice. XXY mice are significantly
osteopenic (p¼.045). Data are mean SEM.
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profound with steroidal withdrawal that additional genotypic
effects on bone mass may have been overwhelmed.
In a strategy to remove the effect of differences in gonadal
function on bone changes in XY and XXY mice, we conducted
in a study in which XXY and XY mice were orchidectomized
but immediately received a testosterone implant. Simultaneous
orchidectomy and testosterone replacement in XXY mice
unveiled persistent osteopenia associated with reduced trabe-
cular number and increased trabecular separation but preserved
trabecular thickness compared with identically treated XY
littermate mice. This testosterone-replacement strategy resulted
in matched testosterone levels comparable with adult XY mice
and was applied for 2 months. The changes in trabecular
architecture differ from those seen in intact XXY mice, and this is
consistent with our contention that the bone phenotype of XXY
mice is partly but not completely due to androgen deficiency.
Histomorphometric analysis failed to identify differences in
bone formation (double tetracycline labeling) or in osteoblast
or osteoclast surfaces between XXY and XY mice in the
intact, orchidectomized, or orchidectomized and testosterone-
replacement studies. The reason for this is unclear but could be
due to establishment of a new steady state in bone turnover at
the time of euthanasia in these mice. Nevertheless, osteopenia
per se in the testosterone-treated whole animal was confirmed
independently by DXA. Importantly, our DXA findings show
equivalent total, lean, and fat mass between hormonally
matchedXXYandXYmice.Thesedataprovidesomereassurance
that the bone findings do not relate to changes in body
composition, physical activity and bone loading, net aromatase
action, growth hormone, or adipokines,
(35) although we did not
measure the latter directly.
We did not show any difference in cortical bone in intact,
castrated,orsimultaneouslycastratedandtestosterone-replaced
mice.Trabecular bonemassis typically amore sensitive indicator
of developing osteoporosis (which is a cause of osteopenia),
but the reason for the maintenance of cortical bone mass
despite loss of trabecular bone is unclear, although cortical and
trabecular bone loss may be subject to different genetic control
in mice.
(36) Such an explanation would be consistent with a
genetic component to bone loss in XXY mice. Androgen effects
are exerted mostly on trabecular bone, whereas aromatization to
estrogens is also important for cortical bone,
(37) although not
exclusively so.
(34,37) This effect on trabecular bone is mediated by
androgen receptors located in mature osteoblasts that are
responsible for bone mineralization.
(34) However, not all studies
agree, and overexpression of androgen receptor actually may
decrease endocortical bone formation.
(38) The reasons for these
discrepancies may relate to ontogeny.
Inconclusion,weprovideevidence,usingamousemodel,that
the osteopenia of KS is not due to just androgen deficiency and
that there is an additional effect of genotype. If this evidence can
be translated to human KS, it would provide a rationale for the
difficulty in normalizing bone mass through androgen therapies
in these patients. Perhaps of greater importance, these finding
encourage further studies that seek to identify X-linked genes
that could contribute to bone loss in KS patients and that would
have broader relevance to osteoporotic patients in general.
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